Our website uses cookies to improve and personalize your experience. Our website may also include cookies from third parties like Google Adsense, Google Analytics, YouTube. By using this website, you consent to the use of cookies. We've updated our Privacy Policy, please click on the button beside to check our Privacy Policy.

International Cancer Institute

Cancer Care, Research Training & Education

Home Medication Access Programs

Medication Access Programs

 

 

 

To ensure that our patients receive high-quality medications that are effective and targeted to specific cancers, International Cancer Institute has partnered with various pharmaceutical companies and foundations, to avail novel agents to our patients that are highly subsidized for those that meet the indications and eligibility criteria.

 

We have the medication access programs for the following:

Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ACLC), a type of T cell non-Hodgkin lymphoma. It selectively targets tumour cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL.

 

Eligibility: Those diagnosed with Hodgkin’s Lymphoma who have CD30+ marker on IHC/pathology and have failed their first-line treatment with ABVD regimen.

 

Check for eligibility, care plans, and booking of appointments by writing to info@intercancer.com with the subject title “ICI Patient Access Program” or call our centre on +254 718 473 446 (Mondays – Fridays from 8 AM – 5 PM) and ask for the Oncology Pharmacist for more information.

Eligibility: Those diagnosed with Non-Hodgkin’s Lymphoma (NHL) or chronic lymphocytic leukaemia and have an indication for Rituximab. Those whose cancers express CD20 positivity.

 

Rituximab is a chimeric monoclonal antibody targeted against CD20 which is a surface antigen present on B cells. Therefore, it acts by depleting normal as well as pathogenic B cells while sparing plasma cells and hematopoietic stem cells as they do not express the CD20 surface antigen.

 

Rituximab may be used to treat cancers of the white blood system such as leukaemias and lymphomas, including non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, and lymphocyte-predominant subtype of Hodgkin’s Lymphoma.

 

We offer a highly subsidized price for Rituximab than the market price in Kenya. This is to increase access to this life-saving targeted therapy for the majority of our patients who have financial constraints.

 

Check for eligibility, care plans and booking of appointments by writing to info@intercancer.com with the subject title “ICI Patient Access Program” or call our centre on +254 718 473 446 (Mondays – Fridays from 8 AM – 5 PM) and ask for the Oncology Pharmacist for more information.

Eligibility:  Those diagnosed with HER 2-positive breast cancer and have an indication for Trastuzumab

 

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer. It is specifically used for cancer that is HER2 receptor-positive. It may be used alone or together with other chemotherapy medication(s).

 

We offer a highly subsidized price for trastuzumab that is 50% or less than the market price in Kenya. This is to increase access to this life-saving targeted therapy for the majority of our patients who have financial constraints.

 

Check for eligibility, care plans and booking of appointments by writing to info@intercancer.com with the subject title “ICI Patient Access Program” or call our centre on +254 718 473 446 (Mondays – Fridays from 8 AM – 5 PM) and ask for the Oncology Pharmacist for more information.

Eligibility: Those diagnosed with Colon Cancer may benefit from our patient access program for Capecitabine/Xeloda.

 

Capecitabine, sold under the brand name Xeloda among others, is a chemotherapy medication used to treat breast cancer, gastric cancer, and colorectal cancer. 

 

Capecitabine is a prescription medicine used to treat people with:

 

  • Cancer of the colon that has spread to lymph nodes in the area close to the colon (Dukes’ C stage) after they have surgery.
  • Cancer of the colon or rectum (colorectal) that has spread to other parts of the body (metastatic).
  • Breast cancer that has spread to other parts of the body (metastatic) together with another medicine called docetaxel after treatment with certain other anticancer medicines that may have not worked.
  • Breast cancer that has spread to other parts of the body and has not improved after treatment with paclitaxel and certain other anti-cancer medicines, or who cannot receive any more treatment with certain anticancer medicines.

 

Check for eligibility, care plans and booking of appointments by writing to info@intercancer.com with the subject title “ICI Patient Access Program” or call our centre on +254 718 473 446 (Mondays – Fridays from 8 AM – 5 PM) and ask for the Oncology Pharmacist for more information.

Eligibility: Those diagnosed with metastatic Prostate cancer (Stage IV).

 

Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically, it is used together with a corticosteroid (Prednisone) for metastatic castration-resistant prostate cancer and metastatic high-risk castration-sensitive prostate cancer.

 

Check for eligibility, care plans and booking of appointments by writing to info@intercancer.com with the subject title “ICI Patient Access Program” or call our centre on +254 718 473 446 (Mondays – Fridays from 8 AM – 5 PM) and ask for the Oncology Pharmacist for more information.

Opening Hours

Monday – Friday 8.00 – 17.00
Weekends Closed
Holidays Closed

Quick Contacts

  • Address P.O. Box 8088-30100, Nandi Rd., Eldoret
  • Phone +254 718 473 446
International Cancer Institute